By Chris Wack

 

4D Molecular Therapeutics Inc. said it received a notice of termination of the collaboration and license agreement by 4D-110 licensee Roche resulting in full rights to 4D-110 for choroideremia reverting to 4D Molecular.

The company said Roche requested that 4D Molecular end the Roche-funded 4D-110 trial in advanced choroideremia patients as a result of Roche's assessment of a change in the risk-benefit profile.

Roche sent a notice of termination without cause effective Sept. 16, with 4D Molecular regaining full rights to 4D-110.

4D Molecular said it hasn't changed its position on the potential of 4D-110 for choroideremia, and intends to continue clinical development. The company said it plans to submit to the Food and Drug Administration safety and efficacy data from the completed Phase 1 clinical trial along with a new clinical study protocol as soon as possible.

The company said it will conclude the Roche-funded clinical trial under the collaboration and plans to subsequently transfer previously treated patients onto a company-sponsored long-term follow-up study to continue monitoring biologic activity endpoints, safety and tolerability.

4D Molecular Therapeutics shares were down 7% to $23 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

June 24, 2021 09:25 ET (13:25 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2021 to Aug 2021 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2020 to Aug 2021 Click Here for more Roche (QX) Charts.